- Heterocyclic kinase inhibitor
-
The invention belongs to the technical field of medicines, and particularly relates to a heterocyclic DNA-PK kinase inhibitor compound shown as a general formula (I), a pharmaceutically acceptable salt and an isomer thereof, a pharmaceutical composition and preparation containing the compound, the pharmaceutically acceptable salt and the isomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt and the isomer thereof, and application of the compound, the pharmaceutically acceptable salt and the isomer thereof.
- -
-
Paragraph 0269; 0273-0275
(2021/03/31)
-
- TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
-
The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.
- -
-
Page/Page column 207
(2011/11/01)
-